curacle co.,ltd. (KOSDAQ:365270)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,280.00
+280.00 (4.00%)
At close: Oct 10, 2025
4.00%
Market Cap98.06B
Revenue (ttm)1.13B
Net Income (ttm)-18.69B
Shares Out14.01M
EPS (ttm)-1,343.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume699,265
Average Volume1,522,649
Open7,060.00
Previous Close7,000.00
Day's Range6,900.00 - 7,450.00
52-Week Range3,600.00 - 9,100.00
Beta1.82
RSI69.76
Earnings Daten/a

About curacle co.,ltd.

Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bow... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 365270
Full Company Profile

Financial Performance

In 2024, curacle co.,ltd.'s revenue was 1.63 billion, a decrease of -84.14% compared to the previous year's 10.29 billion. Losses were -14.89 billion, 28.5% more than in 2023.

Financial Statements

News

There is no news available yet.